Safety profiles and effects of Tualang honey on the levels of inflammation bone markers and oestradiol in breast cancer patients
Honey is traditionally used among breast cancer patients in Malaysia with the belief that it can improve the overall health. However, to our knowledge, no study has reported on the effects of Tualang honey supplementation on safety profiles, inflammatory markers, bone markers and estradiol among...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/56780/1/Dr.%20Zaida%20Zakaria-24%20pages.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Honey is traditionally used among breast cancer patients in Malaysia with the
belief that it can improve the overall health. However, to our knowledge, no study
has reported on the effects of Tualang honey supplementation on safety profiles,
inflammatory markers, bone markers and estradiol among breast cancer patients. The
aim of this study was therefore, to determine safety profile, and effects of Tualang
honey on inflammatory markers, bone markers, and on oestradiol among breast
cancer patients. A randomised controlled-trial was conducted on breast cancer
patients who were treated with anastrozole and recruited from Oncology Clinic,
Universiti Sains Malaysia. The patients were randomised into control and honey
groups. Honey group was supplemented with 20 g/day of Tualang honey for 12
weeks. Blood was collected at pre- and post-interventions to evaluate the safety
profiles, and levels of inflammatory markers, bone markers and oestradiol between
and within the groups. At pre-intervention, haemoglobin, interleukin-6 and carboxyterminal
crosslinked telopeptide of type 1 collagen (CTX) levels were significantly
higher, whereas procollagen type 1 amino-terminal propeptide (P1NP) level was
significantly lower, in control group compared to honey group. There were no
significant differences found for all parameters between two groups at postintervention
after adjustment for confounding factors. In control group, levels of
albumin, alanine aminotransferase, creatinine, interleukin-1 beta, tumour necrosis
factor alpha and CTX at post-intervention (after 12 weeks), were significantly higher compared to their corresponding levels at pre-intervention. In honey group, at postintervention
(after 12 weeks) total white blood cell count, platelet count, creatinine
and P1NP levels were significantly higher whereas CTX level was significantly
lower compared to their corresponding levels at pre-intervention. However, no
significant differences were found for oestradiol levels between and within groups.
In conclusion, the intervention which consists of 20 g daily honey supplementation to
breast cancer patients for 12 weeks was significantly safe, prevented the increased
inflammation, reduced bone resorption and increased bone formation without
changes in estradiol level. These beneficial effects are probably through the action of
phenolic compounds present in Tualang honey which had antioxidant, antiinflammatory
and anticancer properties. These findings may suggest the beneficial
effects of honey supplementation on inflammation and bone among breast cancer
patients treated with anastrozole and the potential use of honey as an adjuvant
therapy. However, further studies are required to elucidate the exact mechanism of
action on these beneficial effects of Tualang honey and monitoring of those
parameters is recommended for longer honey intake. |
|---|